Novavax Inc. ($NVAX) Stock Forecast: Down 5.1% Today

What is Novavax Inc.?

Novavax, Inc. (NVAX) is a biotechnology company specializing in innovative vaccines, including those for infectious diseases like COVID-19.

Why is Novavax Inc. going down?

NVAX stock is down 5.1% on Jun 2, 2026 17:42

• NVAX stock experienced a downtrend today, potentially due to the approaching deadline for investors to join a securities class action lawsuit. This lawsuit alleges misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline, resulting in significant financial setbacks.
• Despite participation in a recent conference to discuss its vaccine technology platform, the negative impact of the pending lawsuit appears to have overshadowed any positive developments for the company.
• NVAX stock's underperformance relative to its peers, despite overall positive market conditions, indicates that investor sentiment may be more influenced by legal uncertainties than company-specific news or market trends.
• The stock showed some improvement on a strong trading day, surpassing the broader market. However, it still closed below its 52-week high, suggesting ongoing concerns related to the lawsuit are impacting investor confidence in Novavax's future prospects.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. (NVAX) Investors of Filing Deadline in Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Kessler Topaz Meltzer & Check, LLP is reminding Novavax, Inc. (NVAX) investors that the deadline to file in a securities class action lawsuit is January 11, 2022. The lawsuit alleges that Novavax made misleading statements regarding its COVID-19 vaccine's Emergency Use Authorization timeline, causing significant losses for investors. Investors who suffered substantial losses during the class period of March 2, 2021, to October 19, 2021, are encouraged to contact the firm.

https://www.newsfilecorp.com/release/109257/Deadline-in-2-Days-Kessler-Topaz-Meltzer-Check-LLP-Reminds-Novavax-Inc.-NVAX-Investors-of-Filing-Deadline-in-Class-Action-Lawsuit-and-Encourages-Investors-with-Substantial-Losses-to-Contact-the-Firm?lang=fr

Novavax fireside chat at 2026 Jefferies Global Healthcare Conference

Novavax (Nasdaq: NVAX) announced its participation in the 2026 Jefferies Global Healthcare Conference in New York, NY. The company is scheduled to host a fireside chat on Thursday, June 4, 2026, from 10:30 a.m. to 11:00 a.m. Eastern Time. A live webcast and 30-day replay of the session will be available on Novavax's investor relations website.

https://www.stocktitan.net/news/NVAX/novavax-to-participate-in-2026-jefferies-global-healthcare-38fmiuifpxqq.html

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

Novavax, Inc. announced its participation in the 2026 Jefferies Global Healthcare Conference, featuring a fireside chat on June 4, 2026, at 10:30 a.m. Eastern Time. A webcast of the event will be available on the company's investor relations website, with a replay accessible for 30 days. Novavax will share insights into its vaccine science and technology platform at the conference, aiming to deliver value through partnering, capital-efficient R&D, and an efficient operating model.

https://www.prnewswire.com/news-releases/novavax-to-participate-in-2026-jefferies-global-healthcare-conference-302787486.html

Novavax Inc. stock underperforms Monday when compared to competitors

Novavax Inc.'s stock (NVAX) fell 4.19% on Monday, closing at $10.51, despite a generally positive trading day for the broader market. The company's stock is now 12.20% below its 52-week high reached on February 26th. The NASDAQ Composite and Dow Jones Industrial Average both saw gains during the same trading session.

https://www.marketwatch.com/data-news/novavax-inc-stock-underperforms-monday-when-compared-to-competitors-62447290-f6acc1b25c9d

Novavax Inc. stock outperforms competitors on strong trading day

Novavax Inc.'s stock (NVAX) rallied 6.30% to $10.97, outperforming the broader stock market, with both the NASDAQ Composite and Dow Jones Industrial Average also seeing gains. Despite the strong performance, the stock closed 8.35% below its 52-week high.

https://www.marketwatch.com/data-news/novavax-inc-stock-outperforms-competitors-on-strong-trading-day-5cef2679-dbebbe9ffc0d

Trending Today

Power Integrations Inc. ($POWI) Stock Forecast: Up 5.0% Today

Paycom Software Inc. ($PAYC) Stock Forecast: Down 5.1% Today

KKR & Co. Inc. Class A ($KKR) Stock Forecast: Down 5.4% Today

Intel Corporation ($INTC) Stock Forecast: Up 5.2% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.2% Today

The Trade Desk Inc ($TTD) Stock Forecast: Down 5.3% Today

Charter Communications Inc. ($CHTR) Stock Forecast: Down 7.3% Today

CMS Energy Corporation ($CMS) Stock Forecast: Down 0.3% Today

PayPal Holdings Inc. ($PYPL) Stock Forecast: Down 5.2% Today

Quidelortho Corpoation ($QDEL) Stock Forecast: Up 10.7% Today

Novavax Inc. Price History

28.04.2026 - NVAX Stock was down 9.9%

• Despite recent insider selling by Ruxandra Draghia Akli, Novavax Inc. experienced a strong bearish movement today.
• The stock had been performing well in the past few days, outperforming competitors and showing consecutive gains.
• However, the stock closed significantly below its 52-week high, indicating some profit-taking by investors.
• The mixed trading day in the market, along with profit-taking and potential concerns about insider selling, might have contributed to the bearish movement in Novavax's stock price today.

26.04.2026 - NVAX Stock was up 6.3%

• Novavax Inc. (NVAX) stock outperformed its competitors and major indices like the NASDAQ Composite and Dow Jones Industrial Average, showcasing resilience and strength in its market position.
• The fluctuation in Novavax's stock price can be attributed to its operating margin percentage, indicating potential financial health and operational efficiency improvements.
• Despite a recent decline, Novavax bounced back with a 4.16% increase, breaking a losing streak and demonstrating investor confidence in the company's future prospects.
• Overall, Novavax's stock movement today reflects both internal financial metrics and broader market trends, positioning the company as a key player in the biotechnology sector with promising growth potential.

29.04.2026 - NVAX Stock was up 5.4%

• Despite a favorable market environment yesterday, Novavax Inc. lagged behind its competitors, possibly due to profit-taking following a recent winning streak.
• The sale of 30,000 NVAX shares by an insider initially sparked some market uncertainty, but its overall impact was neutral, indicating a limited influence on the stock's upward trend.
• Novavax's consistent gains and outperformance relative to its peers reflect positive market sentiment and strong trading sessions driving the surge in the stock.
• While not directly linked to stock movement, Novavax's operating margin percentage in financial data may offer insights into the company's financial well-being and future growth prospects. This factor enhances investor confidence and bolsters the bullish momentum.

13.04.2026 - NVAX Stock was down 5.2%

• Following positive updates like collaborations with Pfizer and Sanofi, Novavax (NVAX) saw a rise in stock value but observed a downward trend in the current trading session.
• The company's weaker market performance compared to its competitors hints at a potential shift in investor sentiment, leading to profit-taking activities or concerns about its future growth.
• Mixed signals from technical indicators signaling a strong buy stance while options data suggests a preference for downside protection, indicating uncertainty surrounding NVAX's future direction.
• Despite recent positive developments propelling Novavax forward as a growth-oriented player in the vaccine industry, persistent challenges related to profitability and debt likely contributed to today's negative market movement.

27.04.2026 - NVAX Stock was up 10.2%

• NVAX stock surged by 13.57% to $10.46, marking the second consecutive day of gains, showcasing strong investor confidence in the company's future prospects.
• The positive market movement could be attributed to the company's promising vaccine development pipeline and potential breakthroughs in the fight against infectious diseases.
• Despite fluctuations in the broader market, NVAX's consistent outperformance indicates a favorable sentiment towards the company's innovative approach and growth potential.
• Investors seem optimistic about NVAX's ability to capitalize on the increasing demand for vaccines, driving the stock price higher amidst a volatile market environment.

20.04.2026 - NVAX Stock was up 5.3%

• NVAX stock has recently lagged behind its competitors, but today's positive movement suggests a potential shift in investor sentiment.
• Analysis indicates a temporary negative sentiment with a positive long-term projection, signaling investors' focus on broader factors beyond short-term fluctuations.
• Novavax's emphasis on entering seasonal booster markets and expanding its vaccine offerings may contribute to the optimistic investor sentiment and the stock's recent upswing.
• Updates on Novavax's advancements in COVID-19 vaccine development and strategic initiatives post-pandemic are likely factors driving confidence in the company's future, reflected in today's positive market performance.

02.05.2026 - NVAX Stock was down 6.2%

• Novavax recently took part in the 2026 Jefferies Global Healthcare Conference to showcase its vaccine technology platform. However, this did not translate into a positive market response for the stock.
• Despite a generally favorable trading day for the broader market, Novavax's stock performed worse than its competitors, closing 4.19% lower.
• AI-driven liquidity mapping analysis for NVAX suggested strong sentiment and potential upside, yet the stock still faced a bearish trend.
• The stock closed below its 52-week high, signaling potential investor concerns about the company's growth prospects or market conditions, contributing to the bearish movement.

02.05.2026 - NVAX Stock was down 5.1%

• NVAX stock experienced a downtrend today, potentially due to the approaching deadline for investors to join a securities class action lawsuit. This lawsuit alleges misleading statements about the COVID-19 vaccine's Emergency Use Authorization timeline, resulting in significant financial setbacks.
• Despite participation in a recent conference to discuss its vaccine technology platform, the negative impact of the pending lawsuit appears to have overshadowed any positive developments for the company.
• NVAX stock's underperformance relative to its peers, despite overall positive market conditions, indicates that investor sentiment may be more influenced by legal uncertainties than company-specific news or market trends.
• The stock showed some improvement on a strong trading day, surpassing the broader market. However, it still closed below its 52-week high, suggesting ongoing concerns related to the lawsuit are impacting investor confidence in Novavax's future prospects.

11.04.2026 - NVAX Stock was down 8.4%

• Novavax has shown positive developments lately, including strong Q1 earnings and partnerships with Pfizer and Sanofi; however, the stock trended bearishly today.
• Investor concerns may have arisen due to the filing of a Form 144 Notice of Proposed Sale of Securities, potentially leading to selling pressure on the stock.
• Participation in the upcoming BofA Securities 2026 Health Care Conference could offer Novavax a platform to address investor uncertainties and restore market confidence.
• Differing opinions from technical indicators signaling a strong buy and options data pointing to downside protection by the "smart money" likely contributed to the bearish sentiment surrounding the stock.

11.04.2026 - NVAX Stock was down 5.6%

• Today, NVAX stock experienced marked bearish activity attributed to profit-taking by investors following a recent strong rally.
• Positive developments, such as a robust Q1 earnings performance, a significant deal with Pfizer, and an expanded partnership with Sanofi, were overshadowed by concerns regarding negative equity and cash depletion, impacting investor confidence.
• The disclosed insider plan to sell securities, according to an SEC filing, likely contributed to the stock's decline.
• NVAX's comparative underperformance against industry peers amid a broader market downturn indicates the potential impact of general market conditions on today's bearish trend.

08.04.2026 - NVAX Stock was up 13.4%

• Novavax's stock experienced a strong bullish movement of 13.98% following a robust Q1 earnings report and positive developments in its COVID-19 vaccine technology, driven by the following factors:
• The announcement of a licensing deal with Pfizer for its Matrix-M adjuvant technology and an expanded partnership with Sanofi boosted investor confidence in the company's future growth potential.
• The unexpected revenue beat in Q1, amounting to $139.5 million, surpassed analysts' expectations and showcased Novavax's ability to pivot towards a licensing model, reducing its reliance on direct vaccine sales.
• Participation in the BofA Securities 2026 Health Care Conference further highlighted Novavax's strategic positioning and potential for future collaborations and advancements in the healthcare industry.
• Despite a slight underperformance compared to competitors on a previous trading day, the overall positive sentiment surrounding Novavax's recent developments and financial outlook contributed to the bullish market movement.

14.04.2026 - NVAX Stock was down 5.0%

• NVAX stock closed at $9.23, showing a bearish movement of 4.05% today.
• Despite recent positive news related to partnerships and earnings, NVAX underperformed its competitors and the broader market.
• The mixed trading session and market sentiment likely played a role in the bearish movement of NVAX stock.
• Investors, especially the "smart money," exhibit caution towards the stock's long-term prospects. Technical indicators lean towards a strong buy, while options data signal a preference for downside protection.